Final results of the ReoPro readministration registry.

[1]  J. J. Griffin,et al.  Benefits and Risks of Abciximab Use in Primary Angioplasty for Acute Myocardial Infarction: The Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial , 2003, Circulation.

[2]  R. Califf,et al.  Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. , 2002, European heart journal.

[3]  R. Jordan,et al.  Abciximab Readministration: Results of the ReoPro Readministration Registry , 2001, Circulation.

[4]  M. Morice,et al.  Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. , 2001, The New England journal of medicine.

[5]  T. Carmody,et al.  Severe delayed thrombocytopenia associated with abciximab (ReoPro) therapy , 2001, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[6]  R. Califf,et al.  Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. , 2000, American heart journal.

[7]  M. Hadamitzky,et al.  Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. , 2000, Journal of the American College of Cardiology.

[8]  D. Mascarenhas,et al.  Abciximab readministration: A single‐operator community‐hospital experience , 1999, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[9]  Y. Gruel,et al.  Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. , 1999, American journal of clinical pathology.

[10]  J. Burchenal,et al.  Randomized, Placebo-Controlled Trial of Platelet Glycoprotein IIb/IIIa Blockade With Primary Angioplasty for Acute Myocardial Infarction , 1998 .

[11]  T. Investigators.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. , 1998, Lancet.

[12]  E. Topol.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade , 1998, The Lancet.

[13]  M. Pfisterer,et al.  Safe use of platelet GP IIb/IIIa inhibitors. , 1998, American heart journal.

[14]  Epilog Investigators,et al.  Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. , 1997, The New England journal of medicine.

[15]  R. Harrington,et al.  Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. , 1997, Circulation.

[16]  D. Kereiakes,et al.  Abciximab-associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion. , 1996, The American journal of cardiology.

[17]  A. Jawad,et al.  Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. , 1995, American journal of clinical pathology.

[18]  H. Weisman,et al.  The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. , 1995, Molecular immunology.

[19]  Epic Investigators,et al.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.

[20]  A. Schreiber,et al.  Heparin-associated thrombocytopenia. , 1980, The New England journal of medicine.

[21]  R. Aster,et al.  Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. , 2002, Blood.